Amiodarone

證據等級: L5

預測適應症: 10 個

Amiodarone: From Ventricular Arrhythmias to Catecholaminergic Polymorphic Ventricular Tachycardia

One-Sentence Summary

Amiodarone is a well-established multi-class antiarrhythmic agent used globally for life-threatening ventricular and supraventricular arrhythmias, though it currently holds no Philippines regulatory approval. The TxGNN model predicts it may be effective for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), a rare inherited arrhythmia triggered by adrenergic stress, with no registered clinical trials and 10 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Not registered in Philippines (no approved indication data available)
Predicted New Indication	Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
TxGNN Prediction Score	99.78%
Evidence Level	L3
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Amiodarone is a uniquely broad-spectrum antiarrhythmic, exerting effects across all four Vaughan Williams classes simultaneously. It blocks Ikr/Iks potassium channels to prolong the action potential duration and effective refractory period (Class III), inhibits sodium channels to slow conduction velocity (Class I), non-competitively blocks beta-adrenergic receptors to reduce sympathetic drive (Class II), and blocks L-type calcium channels (Class IV). This quadruple ionic mechanism provides comprehensive suppression of both reentrant circuits and automatic or triggered ventricular arrhythmias.

CPVT is caused by gain-of-function mutations in RYR2 (ryanodine receptor type 2) or loss-of-function mutations in CASQ2 (calsequestrin 2), leading to uncontrolled calcium release from the sarcoplasmic reticulum during adrenergic stimulation. This calcium overload drives delayed afterdepolarizations (DADs) and triggered activity, precipitating ventricular tachycardia during exercise or emotional stress. Amiodarone’s Class II (beta-blockade) and Class IV (L-type calcium channel blockade) effects can indirectly attenuate this catecholamine-driven calcium overload, forming the mechanistic basis of TxGNN’s prediction.

However, this mechanism is indirect — amiodarone cannot repair the underlying SR calcium leak at its molecular source. Clinically, beta-blockers and flecainide (which directly suppresses RYR2-mediated calcium sparks) are the accepted first-line treatments for CPVT. Amiodarone appears in the literature primarily as a salvage or adjunctive agent in refractory cases, ICD storm management, and acute resuscitation scenarios. The TxGNN high score likely reflects amiodarone’s broad antiarrhythmic coverage and its documented co-use in patients with life-threatening CPVT episodes unresponsive to standard therapy.

Clinical Trial Evidence

Currently no related clinical trials registered for Amiodarone in catecholaminergic polymorphic ventricular tachycardia.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
26513538	2015	Review	Expert Opinion on Pharmacotherapy	Comprehensive review of advances in pharmacological treatment of ventricular arrhythmias; discusses amiodarone’s role in refractory CPVT and other inherited arrhythmia syndromes, noting its use when beta-blockers and flecainide are insufficient
35892906	2022	Retrospective Cohort	Life (Basel)	Systematic review of CPVT patients in China; characterizes RYR2/CASQ2 mutation spectrum, clinical presentations, and arrhythmic outcomes; highlights differences from Western CPVT cohorts in treatment response
39076628	2022	Retrospective Cohort	Reviews in Cardiovascular Medicine	CPVT cohort from a Chinese city; describes clinical characteristics, genetic basis, healthcare utilization, and costs; reinforces beta-blocker dominance in treatment but documents use of add-on antiarrhythmics in refractory cases
22553997	2012	Case Series	PACE	14-year-old with CPVT (CASQ2 mutation) developed ICD storm; flecainide successfully suppressed the arrhythmic cascade after prior antiarrhythmic agents (including amiodarone) failed to terminate the storm — illustrates amiodarone’s limitations in CPVT ICD storm
17125720	2006	Case Report	Revista Española de Cardiología	Arrhythmic storm triggered by ICD discharge in a CPVT patient; amiodarone was included in the acute pharmacological management protocol for electrical storm suppression
37852665	2023	Case Report	BMJ Case Reports	Young child in out-of-hospital cardiac arrest with recurrent pulseless VT/VF requiring 40 defibrillation shocks; ultimately diagnosed with CPVT; amiodarone administered as part of resuscitation when standard guidelines failed — highlights rescue use in acute CPVT arrest
39735866	2024	Case Report	Frontiers in Cardiovascular Medicine	Teenager with refractory CPVT ultimately resolved by right cardiac sympathetic denervation after failed left cardiac sympathetic denervation; documents the escalating treatment ladder including antiarrhythmic drugs
29668588	2018	Case Report	Medicine	9-year-old child with CPVT due to RYR2 c.7580T>G mutation; delayed diagnosis of 6 years; case highlights diagnostic challenges and underlines importance of genetic testing in atypical pediatric presentations
30116135	2018	Case Report	Turk Pediatri Arsivi	2-year-old presenting with sudden cardiac arrest subsequently diagnosed with CPVT; describes acute resuscitation and initiation of antiarrhythmic therapy
22218697	2012	Case Report	Anesthesia and Analgesia	Neonate with compound long QT mutation and refractory VT; multimodal pharmacotherapy with amiodarone, esmolol, and lidocaine alongside ventricular pacing — underscores amiodarone’s place in neonatal refractory arrhythmia management

Philippines Market Information

Amiodarone is currently not registered with the FDA Philippines. There are no approved product licenses, authorized brand names, or approved indications on record. The drug is unavailable through official Philippines regulatory channels.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for amiodarone specifically in CPVT consists entirely of case reports, retrospective cohort studies, and reviews (L3) with no dedicated clinical trials. Beta-blockers and flecainide remain the established standard of care for CPVT, and amiodarone’s documented role is limited to refractory, rescue, and acute resuscitation scenarios. Combined with the absence of Philippines market authorization and unresolved safety data gaps, there is insufficient basis to advance amiodarone as a new CPVT indication at this stage.

To proceed, the following is needed:

Philippines FDA safety data: package insert (warnings, contraindications, and drug interactions) must be retrieved before any safety screening can be completed
Mechanism of action (MOA) data from DrugBank to formally confirm the indirect calcium-modulating and adrenergic-blocking rationale specific to CPVT pathophysiology
Prospective observational registry or controlled pilot data in CPVT patients receiving amiodarone as adjunctive therapy
Drug interaction assessment, particularly with beta-blockers, flecainide, and other CPVT standard-of-care agents that are likely to be co-administered
Review of amiodarone’s approved international indications (FDA USA, EMA) to assess whether CPVT or related inherited arrhythmias are within current label scope
Given the absence of Philippines registration, a regulatory pathway assessment (new drug application vs. expanded access) would be required before any local clinical evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.